1. Home
  2. BCDA vs SVRE Comparison

BCDA vs SVRE Comparison

Compare BCDA & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.27

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Logo SaverOne 2014 Ltd.

SVRE

SaverOne 2014 Ltd.

HOLD

Current Price

$1.40

Market Cap

1.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCDA
SVRE
Founded
N/A
2014
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5M
1.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
BCDA
SVRE
Price
$1.27
$1.40
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
67.0K
362.9K
Earning Date
11-12-2025
12-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$580,536.00
Revenue This Year
N/A
$453.30
Revenue Next Year
N/A
$106.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.19
52 Week Low
$1.00
$1.33
52 Week High
$3.20
$190.80

Technical Indicators

Market Signals
Indicator
BCDA
SVRE
Relative Strength Index (RSI) 41.88 46.16
Support Level $1.23 $1.61
Resistance Level $1.34 $3.85
Average True Range (ATR) 0.08 0.43
MACD -0.01 -0.10
Stochastic Oscillator 17.86 11.82

Price Performance

Historical Comparison
BCDA
SVRE

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About SVRE SaverOne 2014 Ltd.

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.

Share on Social Networks: